CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $67.8333.

Several research firms have recently commented on CGON. Piper Sandler lifted their price target on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Truist Financial upped their target price on CG Oncology from $62.00 to $66.00 and gave the company a “buy” rating in a report on Friday, January 9th. The Goldman Sachs Group reiterated a “buy” rating and set a $82.00 price target on shares of CG Oncology in a research report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Finally, Guggenheim began coverage on CG Oncology in a research report on Tuesday, October 7th. They issued a “buy” rating and a $90.00 target price on the stock.

Insider Activity

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $41.43, for a total transaction of $41,430.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James Mulay sold 11,145 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The disclosure for this sale is available in the SEC filing. Company insiders own 7.40% of the company’s stock.

Institutional Trading of CG Oncology

Several hedge funds have recently added to or reduced their stakes in CGON. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CG Oncology in the fourth quarter worth $27,000. Winthrop Capital Management LLC bought a new position in CG Oncology in the 2nd quarter valued at about $38,000. Strengthening Families & Communities LLC acquired a new position in CG Oncology during the 3rd quarter valued at about $40,000. Comerica Bank increased its stake in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock worth $77,000 after buying an additional 398 shares in the last quarter. Institutional investors own 26.56% of the company’s stock.

CG Oncology Trading Up 4.4%

Shares of CGON opened at $54.34 on Tuesday. CG Oncology has a 52 week low of $14.80 and a 52 week high of $57.88. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of -26.64 and a beta of 1.35. The stock has a 50 day moving average of $45.78 and a 200-day moving average of $38.55.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.57). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.07 million. On average, sell-side analysts predict that CG Oncology will post -1.31 earnings per share for the current fiscal year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.